Abstract
ObjectiveTo date, there are no predictive biomarkers to guide selection of patients with gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional group Trial (SAMIT) was a 2×2...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have